학술논문
Treatment of elderly patients (pts; > 75 years) with 1st line ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL) or endocrine monotherapy (ET) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))
Document Type
Journal
Author
Decker, T.; Brucker, C.; Engel, A.; Fasching, P. A.; Goehler, T.; Jackisch, C.; Janssen, J.; Koehler, A.; Luedtke-Heckenkamp, K.; Lueftner, D.; van Mackelenbergh, M.; Marme, F.; Nusch, A.; Rautenberg, B.; Reimer, T.; Schmidt, M.; Weide, R.; Wimberger, P.; Figueroa, Maslanka S.; Roos, C.; Woeckel, A.
Source
Subject
Language
English
ISSN
22965262